{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T04:55:01Z","timestamp":1774414501790,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1371-4","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T11:26:40Z","timestamp":1500550000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA\u00ae) to the reference product (Humira\u00ae) in patients with active rheumatoid arthritis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2554-0412","authenticated-orcid":false,"given":"Ahmadreza","family":"Jamshidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Gharibdoost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Vojdanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soosan G.","family":"Soroosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Soroush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arman","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ali","family":"Nazarinia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Shakibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Rezaieyazdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Sahebari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asghar","family":"Hajiabbasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Asghar","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najmeh","family":"Mahjourian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin Mohammadinejad","family":"Rashti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,20]]},"reference":[{"key":"1371_CR1","doi-asserted-by":"crossref","unstructured":"B\u00e9rtolo MB, Brenol CV, Schainberg CG, Neubarth F, Lima FAC, Laurindo IM, et al. Atualiza\u00e7\u00e3o do consenso brasileiro no diagn\u00f3stico e tratamento da artrite reumat\u00f3ide. Rev Bras Reumatol. 2007;47:151\u20139.","DOI":"10.1590\/S0482-50042007000300003"},{"issue":"6","key":"1371_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","volume":"7","author":"IB McInnes","year":"2007","unstructured":"McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429\u201342.","journal-title":"Nat Rev Immunol"},{"key":"1371_CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/oxfordjournals.rheumatology.a031494","volume":"39","author":"P Tugwell","year":"2000","unstructured":"Tugwell P. Pharmacoeconomics of drug therapy for rheumatoid arthritis. Rheumatology (Oxford). 2000;39:43\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"9285","key":"1371_CR4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","volume":"358","author":"DM Lee","year":"2001","unstructured":"Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903.","journal-title":"Lancet"},{"key":"1371_CR5","doi-asserted-by":"crossref","unstructured":"Kwoh CK, Anderson LG, Greene JM, Johnson DA, O'Dell JR, Robbins ML, Roberts WN, Simms RW, Yood RA. Guidelines for the management of rheumatoid arthritis: 2002 update-American College ofRheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Arthritis Rheum. 2002;46(2):328-46.","DOI":"10.1002\/art.10148"},{"key":"1371_CR6","doi-asserted-by":"crossref","unstructured":"Alamanos Y, Voulgari PV, Drosos AA, editors. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Seminars in arthritis and rheumatism. 2006;36(3):182-8). WB Saunders.","DOI":"10.1016\/j.semarthrit.2006.08.006"},{"issue":"1","key":"1371_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200422010-00001","volume":"22","author":"TK Kvien","year":"2004","unstructured":"Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(1):1\u201312.","journal-title":"Pharmacoeconomics"},{"key":"1371_CR8","doi-asserted-by":"crossref","unstructured":"Khan MOA, et al. Clinical evaluation of herbal medicines for the treatment of rheumatoid arthritis. Pak J Nutr. 2011;10(1):51-3.","DOI":"10.3923\/pjn.2011.51.53"},{"issue":"3","key":"1371_CR9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","volume":"63","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, Van Tuyl LH, Funovits J, et al. American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573\u201386.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1371_CR10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1590\/S0482-50042012000200002","volume":"52","author":"LMH Mota","year":"2012","unstructured":"Mota LMH, Cruz BA, Brenol CV, Pereira IA, Rezende-Fronza LS, Bertolo MB, et al. 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis. Rev Bras Reumatol. 2012;52(2):152\u201374.","journal-title":"Rev Bras Reumatol"},{"issue":"6","key":"1371_CR11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964\u201375.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1371_CR12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease\u2010modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625\u201339.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1371_CR13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.37711","volume":"65","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Schiff M, Valente R, Van Der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28\u201338.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1371_CR14","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/rheumatology\/37.10.1060","volume":"37","author":"H Menninger","year":"1998","unstructured":"Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R. A 36\u00a0month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Rheumatology. 1998;37(10):1060\u20138.","journal-title":"Rheumatology"},{"issue":"12","key":"1371_CR15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344(12):907\u201316.","journal-title":"N Engl J Med"},{"issue":"5","key":"1371_CR16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"L Putte Van de","year":"2004","unstructured":"Van de Putte L, Atkins C, Malaise M, Sany J, Russell A, Van Riel P, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508\u201316.","journal-title":"Ann Rheum Dis"},{"key":"1371_CR17","unstructured":"Food U. Drug Administration Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Rockville: FDA; 2012. 2015."},{"issue":"1","key":"1371_CR18","doi-asserted-by":"crossref","first-page":"e000010","DOI":"10.1136\/rmdopen-2014-000010","volume":"1","author":"G Casta\u00f1eda-Hern\u00e1ndez","year":"2015","unstructured":"Casta\u00f1eda-Hern\u00e1ndez G, Gonz\u00e1lez-Ram\u00edrez R, Kay J, Scheinberg MA. Biosimilars in rheumatology: what the clinician should know. RMD open. 2015;1(1):e000010.","journal-title":"RMD open"},{"key":"1371_CR19","unstructured":"Medicare Cf, Services M. National health expenditures 2012 highlights. Online verf\u00fcgbar unter http:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/National-HealthExpendData\/Downloads\/highlights.pdf . 2014."},{"issue":"6","key":"1371_CR20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jbspin.2014.03.019","volume":"81","author":"G Castaneda-Hern\u00e1ndez","year":"2014","unstructured":"Castaneda-Hern\u00e1ndez G, Szekanecz Z, Mysler E, Azevedo VF, Guzman R, Gutierrez M, et al. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine. 2014;81(6):471\u20137.","journal-title":"Joint Bone Spine"},{"issue":"9","key":"1371_CR21","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1371_CR22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727\u201335.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1371_CR23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137\u201345.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1371_CR24","first-page":"2288","volume":"29","author":"A Broeder den","year":"2002","unstructured":"den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002;29(11):2288\u201398.","journal-title":"J Rheumatol"},{"key":"1371_CR25","doi-asserted-by":"crossref","unstructured":"Kaur P, Chow V, Zhang N, Markus R. A randomized, single-blind, single-dose, three-arm, parallel group study in healthy subjects demonstrating pharmacokinetic equivalence of proposed biosimilar ABP 501 with adalimumab. United European Gastroenterol J. 2015;3(5S):A606.","DOI":"10.1136\/annrheumdis-2015-208914"},{"issue":"5","key":"1371_CR26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.biologicals.2011.06.006","volume":"39","author":"C Njue","year":"2011","unstructured":"Njue C. Statistical considerations for confirmatory clinical trials for similar biotherapeutic products. Biologicals. 2011;39(5):266\u20139.","journal-title":"Biologicals"},{"issue":"5","key":"1371_CR27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.biologicals.2011.06.004","volume":"39","author":"MP Fletcher","year":"2011","unstructured":"Fletcher MP. Biosimilars clinical development program: confirmatory clinical trials: a virtual\/simulated case study comparing equivalence and non-inferiority approaches. Biologicals. 2011;39(5):270\u20137.","journal-title":"Biologicals"},{"key":"1371_CR28","doi-asserted-by":"crossref","unstructured":"D\u00f6rner T, Strand V, Casta\u00f1eda-Hern\u00e1ndez G, Ferraccioli G, Isaacs JD, Kvien TK, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2012:annrheumdis-2012-202715.","DOI":"10.1136\/annrheumdis-2012-202715"},{"issue":"7","key":"1371_CR29","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","volume":"46","author":"S Bombardieri","year":"2007","unstructured":"Bombardieri S, Ruiz A, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology. 2007;46(7):1191\u20139.","journal-title":"Rheumatology"},{"issue":"suppl 2","key":"1371_CR30","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1136\/ard.62.suppl_2.ii13","volume":"62","author":"M Hochberg","year":"2003","unstructured":"Hochberg M, Tracy J, Hawkins-Holt M, Flores R. Comparison of the efficacy of the tumour necrosis factor \u03b1 blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003;62 suppl 2:ii13\u2013ii6.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1371_CR31","doi-asserted-by":"crossref","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","volume":"7","author":"KJ Aaltonen","year":"2012","unstructured":"Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstr\u00f6m DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e30275.","journal-title":"PLoS One"},{"issue":"3","key":"1371_CR32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/s10165-011-0516-6","volume":"22","author":"T Takeuchi","year":"2012","unstructured":"Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol. 2012;22(3):327\u201338.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"1371_CR33","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12):2563\u201371.","journal-title":"J Rheumatol"},{"key":"1371_CR34","doi-asserted-by":"crossref","unstructured":"Aletaha D, Alasti F, Smolen JS. Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis. 2016;75(8):1479-85.","DOI":"10.1136\/annrheumdis-2015-208324"},{"issue":"1","key":"1371_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4452","volume":"16","author":"GR Burmester","year":"2014","unstructured":"Burmester GR, Matucci-Cerinic M, Mariette X, Navarro-Blasco F, Kary S, Unnebrink K, et al. Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5\u00a0years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther. 2014;16(1):1.","journal-title":"Arthritis Res Ther"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1371-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T16:43:06Z","timestamp":1750783386000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1371-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1371"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1371-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,20]]},"article-number":"168"}}